{
  "id": 181310,
  "name": "SAREPTA THERAPEUTICS",
  "slug": "sarepta-therapeutics",
  "state": "MA",
  "description": "A biopharmaceutical company focused on innovative RNA-based therapeutics",
  "totalSpending": 2510000,
  "filings": 31,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 320000
    },
    {
      "year": 2019,
      "income": 160000
    },
    {
      "year": 2020,
      "income": 400000
    },
    {
      "year": 2021,
      "income": 240000
    },
    {
      "year": 2022,
      "income": 400000
    },
    {
      "year": 2023,
      "income": 320000
    },
    {
      "year": 2024,
      "income": 240000
    },
    {
      "year": 2025,
      "income": 430000
    }
  ],
  "firms": [
    "TARPLIN, DOWNS & YOUNG, LLC"
  ],
  "lobbyists": [
    "RAISSA DOWNS",
    "JENNIFER YOUNG",
    "MICHELLE EASTON",
    "ELIZABETH MURRAY",
    "CHARLOTTE IVANCIC",
    "PAMELA SMITH",
    "EMILY MURRY",
    "KIMBERLY BRANDT",
    "MARGARET JOSEPH",
    "PETER FISE",
    "LAURA FRIEDEL",
    "PARICK CARROLL"
  ],
  "issues": [
    "HCR",
    "MMM",
    "BUD",
    null
  ],
  "sampleDescriptions": [
    "PL 114-255 - 21st Century Cures, implementation\nS. 204 - Right to Try Act of 2017\nS. 456 - RACE for Children Act\nS. 771 - Improving Access to Affordable Prescription Drugs Act\nS. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017\nStopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017\nS. 469 - Affordable and Safe Prescription Drug Importation act\nH.R. 749 - Lower Drug Costs Through Competition Act\nH.R. 2430 - FDA Reauthorization Act of 2017\n\nno specific bills: Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference",
    "Medicaid Drug Rebate Program, coverage, state program operations, waivers\nH.R. 3921 - Healthy Kids Act\nS. 1827 - Kids Act of 2017",
    "H.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\n\nno specific bill, appropriations",
    "H.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\nH.R. 6157 - HHS appropriations and continuing resolution\n\n\nno specific bill, appropriations",
    "H.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\nH.R. 6157 - HHS appropriations and continuing resolution\nH.R. 695 - Department of Defense Appropriations Act\n\n\nno specific bill, appropriations",
    "H.J.Res. 31 - Consolidated Appropriations Act, 2019\n\nno specific bill, appropriations",
    "Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting\nH.R. 259 - Medicaid Extenders Act of 2019\nH.R. 1839 - Medicaid Services Investment and Accountability Act of 2019",
    "no specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy",
    "S. 1895 - Lower Health Care Costs Act\n\nno specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy",
    "H.R. 3164 - FDA Appropriations, 2020",
    "H.R. 4378 - Continuing Appropriations Act and Health Extenders Act\nH.R. 1865 - Further Consolidated Appropriations Act, 2020\nH.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act",
    "S. 1895 - Lower Health Care Costs Act\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020\nH.R. 6201 - Families First Coronavirus Response Act\nS. 3548 - CARES Act\n\nno specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy",
    "Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting\nH.R. 259 - Medicaid Extenders Act of 2019\nH.R. 1839 - Medicaid Services Investment and Accountability Act of 2019\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act",
    "S. 1895 - Lower Health Care Costs Act\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\n\nno specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy",
    "H.R. 4378 - Continuing Appropriations Act and Health Extenders Act\nH.R. 1865 - Further Consolidated Appropriations Act, 2020\nH.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act\nH.R. 8337 - Continuing Appropriations Act of 2021",
    "Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid Value Based Payment rule \n\nH.R. 259 - Medicaid Extenders Act of 2019\nH.R. 1839 - Medicaid Services Investment and Accountability Act of 2019\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\nH.R. 133 - Consolidated Appropriations Act, 2021",
    "S. 1895 - Lower Health Care Costs Act\nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\nH.R. 133 - Consolidated Appropriations Act, 2021\n\nno specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy",
    "H.R. 4378 - Continuing Appropriations Act and Health Extenders Act\nH.R. 1865 - Further Consolidated Appropriations Act, 2020\nH.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act\nH.R. 8337 - Continuing Appropriations Act of 2021\nH.R. 133 - Consolidated Appropriations Act, 2021",
    "S. Con. Res. 5 (117)",
    "H.R. 1319, American Rescue Plan of 2021\n\n\nno specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 34,
  "trajectory": "growing",
  "yearsActive": 8,
  "avgAnnualSpending": 313750,
  "peakYear": 2025,
  "lobbyistCount": 12,
  "firmCount": 1,
  "issueCount": 3
}